

MMA, Private Plans, and Competition: Formulary Design - Balancing Cost and Access

Harvey Maldow R.Ph., M.S.
Director, Professional Relations
AstraZeneca

The Second National Medicare
Prescription Drug Congress
November 1, 2005

Issues for the Pharmaceutical Industry

- Will there be less granularity in the next version?
- Will the process be more transparent and inclusive?
- What will USP's advisory role be relative to the exempt categories?

Issues for the Pharmaceutical Industry

- Access for patients to necessary medications
- Appeals process variations
 - ◆ Will anyone use the process?

Issues for the Pharmaceutical Industry

- Quality Measures must not be about cost but about patient outcomes
- Generic to Brand Ratio should not be a quality indicator

Issues for the Pharmaceutical Industry

- The program should evolve like private plans
- What happens over time when plans are at full risk?
 - ◆ Will formularies become more restrictive?
- Competition is a good thing

Issues for the Pharmaceutical Industry

- The total cost of Step Therapy Programs
- Generics are not always cheaper
- Seniors can get confused with frequent changes in medications
- How will less granularity impact fragile seniors